Translational advances regarding hereditary breast cancer syndromes.
Approximately 5-10% of breast cancers may be inheritable, up to 90% of which are due to mutations in BRCA1 and BRCA2. A substantial minority are caused by non-BRCA mutations, such as TP53, PTEN, STK11, CHEK2, ATM, BRIP1, and PALB2 mutations. This review highlights translational research advances with regard to the development of probabilistic models for hereditary breast cancer syndromes, the identification of specific genetic mutations responsible for these syndromes, as well as their testing and interpretations.
National Capital Area Breast Care Center, National Naval Medical Center, Bethesda, Maryland, USA.
SourceJournal of surgical oncology 105:5 2012 Apr 1 pg 444-51
Ataxia Telangiectasia Mutated Proteins
Cell Cycle Proteins
Checkpoint Kinase 2
Genetic Predisposition to Disease
Hamartoma Syndrome, Multiple
Hereditary Breast and Ovarian Cancer Syndrome
Neoplastic Syndromes, Hereditary
Translational Medical Research
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
Pub Type(s)Journal Article